Pred-455 [updated] 🔥 Safe

Despite its promising therapeutic potential, the development of PRED-455 has been slow, and its current status is uncertain. Shionogi announced in 2005 that it would discontinue the development of PRED-455 due to concerns about its clinical efficacy and safety profile. However, some research groups have continued to investigate the therapeutic effects of PRED-455 in various anxiety disorders.

In clinical trials, PRED-455 has been evaluated in several studies, including a phase II trial in patients with GAD and a phase I trial in healthy volunteers. The results of these studies indicate that PRED-455 is well-tolerated and produces significant anxiolytic effects, as measured by standardized rating scales, such as the Hamilton Anxiety Rating Scale (HAM-A). PRED-455

PRED-455 acts as a potent and selective agonist at the 5-HT1A receptor, a subtype of the serotonin receptor. By activating this receptor, PRED-455 increases the release of neurotransmitters, such as dopamine, norepinephrine, and serotonin, which are involved in regulating mood, anxiety, and cognitive function. This mechanism is distinct from that of benzodiazepines, which enhance the activity of GABA, an inhibitory neurotransmitter. As a result, PRED-455 is expected to produce anxiolytic effects without the sedative and dependence liabilities associated with benzodiazepines. In clinical trials, PRED-455 has been evaluated in